Moderate to Severe Asthma: News

• ATS 2022 NAVIGATOR Steers Uncontrolled Asthma Toward Calmer Seas The phase 3 trial showed high complete response rates and reduced disease burden with tezepelumab vs placebo.
  Medscape Medical News, May 18, 2022
• Albuterol-Budesonide Combo Offers Better Rescue Therapy for Moderate to Severe Asthma Among patients with uncontrolled moderate to severe asthma, a fixed-dose combination of albuterol and budesonide gives better as-needed relief than albuterol alone, a large international study shows.
  Reuters Health Information, May 16, 2022
• More Evidence Links Asthma Severity to Age of Onset A large, international database study provides further evidence that age of asthma onset influences exacerbations and comorbidities.
  Medscape Medical News, April 27, 2022
• Gaps in Follow-Up Put Kids With Asthma at Risk of Recurrence A new study found that kids were less likely to return to the emergency room for an asthma problem if they had a follow-up visit within a few weeks of the hospital visit.
  Medscape Medical News, April 12, 2022
• Biologic Reduces Corticosteroid Use in Severe Asthma Dupilumab sustains reductions in oral corticosteroid use, and lung function continues to improve during longer-term follow-up.
  Medscape Medical News, March 22, 2022
• Dealing With Life-Threatening Asthma Attacks If a severe asthma exacerbation does not resolve relatively quickly, it's time to look for other clues behind a patient's respiratory distress.
  Medscape Medical News, March 17, 2022
• AAAAI 2022 Asthma: Easy Strategy Reduces Exacerbations, Improves Control Black and Latino asthma patients who self-administered inhaled steroids each time they used rescue medication reduced their annual rate of asthma attacks by 15% in a phase 4 trial.
  Medscape Medical News, February 28, 2022
• Alert FDA Approves First-in-Class Drug for Severe Asthma The US Food and Drug Administration has granted early approval to Tezspire (tezepelumab-ekko) for the add-on maintenance treatment of patients age 12 years and older with severe asthma.
  FDA Approvals, December 20, 2021
• Early Diagnosis of Bronchiectasis Critical in T2 Severe Asthma Type 2 inflammation may be causative in bronchiectasis in patients with type 2-high severe asthma. Its early diagnosis is critical to improve outcomes in patients with this dual diagnosis.
  Medscape Medical News, December 10, 2021
• Dupilumab Cuts Severe Asthma Exacerbations in Children Adding dupilumab to conventional therapy for children with uncontrolled moderate-to-severe asthma reduces the risk of severe exacerbations by 59%, according to results from a year-long study.
  Reuters Health Information, December 08, 2021
• Poorly Controlled Asthma Predicts COVID-19 Hospitalization in Kids Children and adolescents with poorly controlled asthma were three to six times more likely to be hospitalized with COVID-19 infections.
  Medscape Medical News, December 02, 2021
• ACR 2021 Risankizumab Outperforms Placebo at 6 Months for Psoriatic Arthritis At the 24-week assessment, participants receiving risankizumab showed greater improvement in primary and secondary endpoints than did placebo with no new safety signals.
  Medscape Medical News, November 08, 2021
• SLIT Safe for Asthma, but Efficacy Data Are Lacking Sublingual immunotherapy appears safe for allergy, but new research suggests that although it's safe for patients with asthma, there's insufficient evidence on its efficacy in asthma management.
  Medscape Medical News, November 05, 2021
• Placebo Beat Risankizumab in Adults With Severe Asthma Risankizumab, a humanized, monoclonal antibody approved for the treatment of moderate to severe psoriasis, underperformed placebo in adults with severe asthma.
  Medscape Medical News, October 27, 2021
• Itepekimab Reduces Loss of Asthma Control Treatment with itepekimab, a new human IgG4P monoclonal antibody against interleukin-33, led to a reduction in events indicating loss of asthma control.
  Medscape Medical News, October 27, 2021
• CHEST 2021 Dupilumab-Improved Lung Function Lasts in Children With Asthma Add-on treatment with dupilumab may improve lung function in children aged 6-11 years with uncontrolled moderate to severe type 2 inflammatory asthma, results from a phase 3 study show.
  Medscape Medical News, October 18, 2021
• Tree Nut Storage Proteins Best for Predicting Allergy Tree nut extract sensitization is often asymptomatic and is a less accurate predictor of allergy in young adulthood.
  Medscape Medical News, August 31, 2021
• EAACI 2021 Tezepelumab Reduces Asthma Exacerbation Rates by 56% The biologic reduced the annualized exacerbation rate in a broad group of patients with severe asthma by 56% in the phase 3 NAVIGATOR trial.
  Medscape Medical News, July 14, 2021
• EAACI 2021 Short-Acting Beta Agonist Overuse 'a Global Public Health Issue' Overreliance on SABAs and underuse of inhaled corticosteroids are associated with increased risk of exacerbations and asthma-related death.
  Medscape Medical News, July 11, 2021
• EAACI 2021 Dupilumab Safe, Effective in Kids With Moderate-to-Severe Asthma Adding the dupilumab option for children in this age group is "huge," says one expert.
  Medscape Medical News, July 10, 2021